Forbes January 16, 2019
David Shaywitz

The current challenge for data science and technology (DST) in healthcare is moving beyond the “dancing bear” stage, where “the wonder is not how well the bear dances, but that he dances at all.” It’s time for DST to evolve past the novelty publications and the click bait, and demonstrate its ability to materially impact health and disease.

Narasimhan assumed the reigns as CEO a year ago, emphasizing the importance of digital and data for pharma R&D. Now, a year into his tenure, he reflects on how the technology integration effort has been going.

The need for DST impact in pharma is especially acute, and challenging, as this column has critically...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Big Data, Digital Health, Market Research, Pharma, Technology, Trends
Will The White House’s Plan To Curb Drug Shortages Work?
Pharma Pulse 4/24/24: 5 Things You Should Know About Women's Health, Microsoft Makes Push Into Smaller AI Systems & more
New AI drug discovery powerhouse Xaira rises with $1B in funding
AI-enabled drug discovery company Xaira launches with $1B
25 most expensive hospital drugs

Share This Article